The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
The SELECT study: A multicenter phase II trial of adjuvant erlotinib in resected epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).
Joel W. Neal
Research Funding - Genentech
Nathan A. Pennell
Consultant or Advisory Role - Boehringer Ingelheim; Oncogenex
Research Funding - Genentech
Ramaswamy Govindan
Consultant or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Genentech; GlaxoSmithKline; Pfizer
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Genentech; GlaxoSmithKline; Pfizer
Research Funding - Genentech
Michael Lanuti
Consultant or Advisory Role - Boston Scientific
Rachel Pam Greenerger Rosovsky
No relevant relationships to disclose
Rebecca Suk Heist
No relevant relationships to disclose
Alice Tsang Shaw
Consultant or Advisory Role - ARIAD; Chugai Pharma; Daiichi Sankyo; Pfizer
Honoraria - Novartis
Research Funding - AstraZeneca; Novartis
Jennifer S. Temel
No relevant relationships to disclose
Alona Muzikansky
No relevant relationships to disclose
Pasi A. Janne
Consultant or Advisory Role - Genentech; OSI Pharmaceuticals; Roche
Other Remuneration - LabCorp
Thomas James Lynch
Employment or Leadership Position - Infinity
Consultant or Advisory Role - Astex Therapeutics; Boehringer Ingelheim; Merck
Stock Ownership - Infinity
Honoraria - Astex Therapeutics; Boehringer Ingelheim; Merck
Other Remuneration - Partners Healthcare
Christopher G. Azzoli
Research Funding - Genentech
Lecia V. Sequist
Consultant or Advisory Role - Celgene; Clovis Oncology; Daiichi Sankyo (U); GlaxoSmithKline; Merrimack (U)
Research Funding - Genentech